Differential profiling of prostate tumors versus benign prostatic tissues by using a 2DE-MALDI-TOF-based proteomic approach
Oncoproteomic technologies offer a complementary approach to the understanding of cancer proteins' function and the translation of molecular knowledge into clinical practice. Our aim was to compare the proteomic profiles of prostate tumors versus benign prostatic hyperplasia (BPH) tissues in or...
Gespeichert in:
| Veröffentlicht in: | Neoplasma 2021-01, Vol.68 (1), p.154-164 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 164 |
|---|---|
| container_issue | 1 |
| container_start_page | 154 |
| container_title | Neoplasma |
| container_volume | 68 |
| creator | Kmeťová Sivoňová, Monika Tatarková, Zuzana Jurečeková, Jana Kliment, Ján Híveš, Márk Lichardusová, Lucia Kaplán, Peter |
| description | Oncoproteomic technologies offer a complementary approach to the understanding of cancer proteins' function and the translation of molecular knowledge into clinical practice. Our aim was to compare the proteomic profiles of prostate tumors versus benign prostatic hyperplasia (BPH) tissues in order to identify modulated proteins as the potential biomarkers for prostate cancer. Proteins extracted from twenty prostate cancer tissue specimens and ten BPH tissues were analyzed by two-dimensional electrophoresis (2-DE) coupled with MALDI-TOF mass spectrometry. Western blot and quantitative real-time PCR (RT-PCR) were performed to confirm the different amounts of protein biomarkers revealed by 2DE combined with MALDI mass spectrometry. We found 42 spots whose expression in the prostate was altered more than 1.5-fold compared with BPH tissue (p |
| doi_str_mv | 10.4149/neo_2020_200611N625 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2446664889</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2446664889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-4c637cf7c0819284afa7bcd2bdd210f1cd3794d65af95fc9bc5c291e893a5dbc3</originalsourceid><addsrcrecordid>eNptkMtOwzAQRS0EolXpFyAhL9kY_E68rPqASoVuyjpyHLsY5VHiBKni53FUygovxh7NnLmeC8AtwQ-ccPVY2yajmOIYsCTkVVJxAcaEsRRxRpJLMMaYpojKVIzANIQPHI8UmFJyDUaMqiRJKBuD74V3zra27rwu4aFtnC99vYeNG5LQ6c7Crq-aNsAv24Y-wNzWfl-fq97AzofQ21g4wj4MrIZ0sUQvs81ijXbbFcp1sMUAdLapIqAP8a3N-w24croMdvp7T8DbarmbP6PN9mk9n22QYQJ3iBvJEuMSg1OiaMq100luCpoXBSXYEVOwRPFCCu2UcEblRhiqiE0V06LIDZuA-9PcKPsZf9pllQ_GlqWOLvYho5xLKXkagQlgp1YT1wutddmh9ZVujxnB2WB89o_xkbr7FejzyhZ_zNlm9gP8z4Fn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2446664889</pqid></control><display><type>article</type><title>Differential profiling of prostate tumors versus benign prostatic tissues by using a 2DE-MALDI-TOF-based proteomic approach</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Kmeťová Sivoňová, Monika ; Tatarková, Zuzana ; Jurečeková, Jana ; Kliment, Ján ; Híveš, Márk ; Lichardusová, Lucia ; Kaplán, Peter</creator><creatorcontrib>Kmeťová Sivoňová, Monika ; Tatarková, Zuzana ; Jurečeková, Jana ; Kliment, Ján ; Híveš, Márk ; Lichardusová, Lucia ; Kaplán, Peter</creatorcontrib><description>Oncoproteomic technologies offer a complementary approach to the understanding of cancer proteins' function and the translation of molecular knowledge into clinical practice. Our aim was to compare the proteomic profiles of prostate tumors versus benign prostatic hyperplasia (BPH) tissues in order to identify modulated proteins as the potential biomarkers for prostate cancer. Proteins extracted from twenty prostate cancer tissue specimens and ten BPH tissues were analyzed by two-dimensional electrophoresis (2-DE) coupled with MALDI-TOF mass spectrometry. Western blot and quantitative real-time PCR (RT-PCR) were performed to confirm the different amounts of protein biomarkers revealed by 2DE combined with MALDI mass spectrometry. We found 42 spots whose expression in the prostate was altered more than 1.5-fold compared with BPH tissue (p<0.05). These spots represented ten different proteins that were identified by a database search after mass spectrometry: they comprised proteins involved in the regulation of actin dynamics, the cytoskeleton, and cell motility (ACTG2, ACTA2, TPM1, DES, VIM, FLNA, and TAGLN), heat shock protein-27 (Hsp27), and proteins with other functions (TR and RANBP3). Subsequent western blot and RT-PCR assays for DES, VIM, TAGLN, and Hsp27 in prostate tumor tissues and BPH tissues confirmed the observations obtained by proteomic analysis. The cytoskeletal and cytoskeleton-associated proteins identified by this approach might be useful molecular targets for prostate cancer diagnostics and may contribute to novel therapies for prostate cancer.</description><identifier>ISSN: 0028-2685</identifier><identifier>ISSN: 1338-4317</identifier><identifier>EISSN: 1338-4317</identifier><identifier>DOI: 10.4149/neo_2020_200611N625</identifier><identifier>PMID: 32977723</identifier><language>eng</language><publisher>Slovakia</publisher><subject>Actins - metabolism ; Biomarkers, Tumor - metabolism ; Diagnosis, Differential ; Humans ; Male ; Prostatic Hyperplasia - diagnosis ; Prostatic Hyperplasia - metabolism ; Prostatic Hyperplasia - pathology ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - pathology ; Proteomics ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><ispartof>Neoplasma, 2021-01, Vol.68 (1), p.154-164</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c350t-4c637cf7c0819284afa7bcd2bdd210f1cd3794d65af95fc9bc5c291e893a5dbc3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32977723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kmeťová Sivoňová, Monika</creatorcontrib><creatorcontrib>Tatarková, Zuzana</creatorcontrib><creatorcontrib>Jurečeková, Jana</creatorcontrib><creatorcontrib>Kliment, Ján</creatorcontrib><creatorcontrib>Híveš, Márk</creatorcontrib><creatorcontrib>Lichardusová, Lucia</creatorcontrib><creatorcontrib>Kaplán, Peter</creatorcontrib><title>Differential profiling of prostate tumors versus benign prostatic tissues by using a 2DE-MALDI-TOF-based proteomic approach</title><title>Neoplasma</title><addtitle>Neoplasma</addtitle><description>Oncoproteomic technologies offer a complementary approach to the understanding of cancer proteins' function and the translation of molecular knowledge into clinical practice. Our aim was to compare the proteomic profiles of prostate tumors versus benign prostatic hyperplasia (BPH) tissues in order to identify modulated proteins as the potential biomarkers for prostate cancer. Proteins extracted from twenty prostate cancer tissue specimens and ten BPH tissues were analyzed by two-dimensional electrophoresis (2-DE) coupled with MALDI-TOF mass spectrometry. Western blot and quantitative real-time PCR (RT-PCR) were performed to confirm the different amounts of protein biomarkers revealed by 2DE combined with MALDI mass spectrometry. We found 42 spots whose expression in the prostate was altered more than 1.5-fold compared with BPH tissue (p<0.05). These spots represented ten different proteins that were identified by a database search after mass spectrometry: they comprised proteins involved in the regulation of actin dynamics, the cytoskeleton, and cell motility (ACTG2, ACTA2, TPM1, DES, VIM, FLNA, and TAGLN), heat shock protein-27 (Hsp27), and proteins with other functions (TR and RANBP3). Subsequent western blot and RT-PCR assays for DES, VIM, TAGLN, and Hsp27 in prostate tumor tissues and BPH tissues confirmed the observations obtained by proteomic analysis. The cytoskeletal and cytoskeleton-associated proteins identified by this approach might be useful molecular targets for prostate cancer diagnostics and may contribute to novel therapies for prostate cancer.</description><subject>Actins - metabolism</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Diagnosis, Differential</subject><subject>Humans</subject><subject>Male</subject><subject>Prostatic Hyperplasia - diagnosis</subject><subject>Prostatic Hyperplasia - metabolism</subject><subject>Prostatic Hyperplasia - pathology</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Proteomics</subject><subject>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><issn>0028-2685</issn><issn>1338-4317</issn><issn>1338-4317</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkMtOwzAQRS0EolXpFyAhL9kY_E68rPqASoVuyjpyHLsY5VHiBKni53FUygovxh7NnLmeC8AtwQ-ccPVY2yajmOIYsCTkVVJxAcaEsRRxRpJLMMaYpojKVIzANIQPHI8UmFJyDUaMqiRJKBuD74V3zra27rwu4aFtnC99vYeNG5LQ6c7Crq-aNsAv24Y-wNzWfl-fq97AzofQ21g4wj4MrIZ0sUQvs81ijXbbFcp1sMUAdLapIqAP8a3N-w24croMdvp7T8DbarmbP6PN9mk9n22QYQJ3iBvJEuMSg1OiaMq100luCpoXBSXYEVOwRPFCCu2UcEblRhiqiE0V06LIDZuA-9PcKPsZf9pllQ_GlqWOLvYho5xLKXkagQlgp1YT1wutddmh9ZVujxnB2WB89o_xkbr7FejzyhZ_zNlm9gP8z4Fn</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Kmeťová Sivoňová, Monika</creator><creator>Tatarková, Zuzana</creator><creator>Jurečeková, Jana</creator><creator>Kliment, Ján</creator><creator>Híveš, Márk</creator><creator>Lichardusová, Lucia</creator><creator>Kaplán, Peter</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202101</creationdate><title>Differential profiling of prostate tumors versus benign prostatic tissues by using a 2DE-MALDI-TOF-based proteomic approach</title><author>Kmeťová Sivoňová, Monika ; Tatarková, Zuzana ; Jurečeková, Jana ; Kliment, Ján ; Híveš, Márk ; Lichardusová, Lucia ; Kaplán, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-4c637cf7c0819284afa7bcd2bdd210f1cd3794d65af95fc9bc5c291e893a5dbc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Actins - metabolism</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Diagnosis, Differential</topic><topic>Humans</topic><topic>Male</topic><topic>Prostatic Hyperplasia - diagnosis</topic><topic>Prostatic Hyperplasia - metabolism</topic><topic>Prostatic Hyperplasia - pathology</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Proteomics</topic><topic>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kmeťová Sivoňová, Monika</creatorcontrib><creatorcontrib>Tatarková, Zuzana</creatorcontrib><creatorcontrib>Jurečeková, Jana</creatorcontrib><creatorcontrib>Kliment, Ján</creatorcontrib><creatorcontrib>Híveš, Márk</creatorcontrib><creatorcontrib>Lichardusová, Lucia</creatorcontrib><creatorcontrib>Kaplán, Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neoplasma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kmeťová Sivoňová, Monika</au><au>Tatarková, Zuzana</au><au>Jurečeková, Jana</au><au>Kliment, Ján</au><au>Híveš, Márk</au><au>Lichardusová, Lucia</au><au>Kaplán, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential profiling of prostate tumors versus benign prostatic tissues by using a 2DE-MALDI-TOF-based proteomic approach</atitle><jtitle>Neoplasma</jtitle><addtitle>Neoplasma</addtitle><date>2021-01</date><risdate>2021</risdate><volume>68</volume><issue>1</issue><spage>154</spage><epage>164</epage><pages>154-164</pages><issn>0028-2685</issn><issn>1338-4317</issn><eissn>1338-4317</eissn><abstract>Oncoproteomic technologies offer a complementary approach to the understanding of cancer proteins' function and the translation of molecular knowledge into clinical practice. Our aim was to compare the proteomic profiles of prostate tumors versus benign prostatic hyperplasia (BPH) tissues in order to identify modulated proteins as the potential biomarkers for prostate cancer. Proteins extracted from twenty prostate cancer tissue specimens and ten BPH tissues were analyzed by two-dimensional electrophoresis (2-DE) coupled with MALDI-TOF mass spectrometry. Western blot and quantitative real-time PCR (RT-PCR) were performed to confirm the different amounts of protein biomarkers revealed by 2DE combined with MALDI mass spectrometry. We found 42 spots whose expression in the prostate was altered more than 1.5-fold compared with BPH tissue (p<0.05). These spots represented ten different proteins that were identified by a database search after mass spectrometry: they comprised proteins involved in the regulation of actin dynamics, the cytoskeleton, and cell motility (ACTG2, ACTA2, TPM1, DES, VIM, FLNA, and TAGLN), heat shock protein-27 (Hsp27), and proteins with other functions (TR and RANBP3). Subsequent western blot and RT-PCR assays for DES, VIM, TAGLN, and Hsp27 in prostate tumor tissues and BPH tissues confirmed the observations obtained by proteomic analysis. The cytoskeletal and cytoskeleton-associated proteins identified by this approach might be useful molecular targets for prostate cancer diagnostics and may contribute to novel therapies for prostate cancer.</abstract><cop>Slovakia</cop><pmid>32977723</pmid><doi>10.4149/neo_2020_200611N625</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-2685 |
| ispartof | Neoplasma, 2021-01, Vol.68 (1), p.154-164 |
| issn | 0028-2685 1338-4317 1338-4317 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2446664889 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Actins - metabolism Biomarkers, Tumor - metabolism Diagnosis, Differential Humans Male Prostatic Hyperplasia - diagnosis Prostatic Hyperplasia - metabolism Prostatic Hyperplasia - pathology Prostatic Neoplasms - diagnosis Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Proteomics Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization |
| title | Differential profiling of prostate tumors versus benign prostatic tissues by using a 2DE-MALDI-TOF-based proteomic approach |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A34%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20profiling%20of%20prostate%20tumors%20versus%20benign%20prostatic%20tissues%20by%20using%20a%202DE-MALDI-TOF-based%20proteomic%20approach&rft.jtitle=Neoplasma&rft.au=Kme%C5%A5ov%C3%A1%20Sivo%C5%88ov%C3%A1,%20Monika&rft.date=2021-01&rft.volume=68&rft.issue=1&rft.spage=154&rft.epage=164&rft.pages=154-164&rft.issn=0028-2685&rft.eissn=1338-4317&rft_id=info:doi/10.4149/neo_2020_200611N625&rft_dat=%3Cproquest_cross%3E2446664889%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2446664889&rft_id=info:pmid/32977723&rfr_iscdi=true |